VENTYX BIOSCIENCES, INC.
Ventyx Biosciences, Inc. (VTYX) is a small‑cap biotechnology company listed in the US market with a market capitalisation of about $268.12 million. As an R&D‑focused issuer, Ventyx’s value is driven primarily by its scientific pipeline, clinical‑trial progress, regulatory milestones and partnerships rather than steady operating profits. Biotech stocks of this size often experience high volatility: positive trial news or regulatory approvals can lift the share price quickly, while setbacks, funding needs or disappointing data can lead to sharp declines. Income investors should not expect dividends; returns typically come from capital appreciation. Before considering any exposure, investors should review the company’s latest filings, understand the clinical stage of its programmes, assess cash runway and funding plans, and be comfortable with possible dilution and binary event risk. This summary is for general educational purposes only and is not personalised investment advice — values can rise and fall and past performance is not a reliable indicator of future results.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Ventyx Biosciences stock, expecting its value to rise to $13.
Financial Health
VENTYX BIOSCIENCES is performing well with solid cash flow and a decent book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring VTYX
Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketLottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small‑cap dynamics
Market moves can be large and rapid for a ~$268m company, offering potential upside but also heightened volatility and liquidity risk.
Pipeline & trials
Clinical progress and regulatory news typically drive value. Check trial phases and read peer comparisons, though outcomes can be binary.
Funding considerations
R&D costs may require future capital raises, which can dilute shareholders; assess cash runway and management funding plans.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
